1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
MPX International Corp.

MPX International Corp.

MPXOF
MPX International Corp.US flagOther OTC
0.00
USD
- -
- -
14,432.00Market Cap
MPX International Corp.
MPXOF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
TTM
FRC
- -
0.02
0.02
0.05
0.05
Revenue per Share
-0.04
-0.13
-0.29
-0.19
-0.2
Basic EPS, GAAP
-0.1
-0.21
-0.12
-0.09
-0.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
0.79
0.13
-0.05
-0.12
Book Value per Share
0.06
0.35
0.01
0.02
-0.06
Tangible Book Value per Share
51
72
140
143
144
Basic Weighted Avg Shares
- -
2
3
7
7
Sales/Revenue/Turnover
-3,234.78
-399.68
-505.51
-194.68
-244.63
Operating Margin (%)
1
3
5
6
7
Depreciation Expense
-2
-9
-41
-27
-28
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,266.35
-589.27
-1,294.2
-369.38
-423.71
Profit Margin (%)
- -
23
-1
-2
-10
Working Capital
1
1
9
12
17
LT Debt
26
69
34
23
10
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-33.02
-108.85
- -
-154.29
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'21
Dec'22
Mar'22
ST Debt
7
7
8
LT Borrowings
7
9
14
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
144
144
144
Market Capitalization
10
5
5

Working Capital

FRC

•

in mil. unless spec.
Sep'21
Dec'22
Mar'22
Total Current Assets
13
10
8
Cash, Cash Equivalents & STI
6
4
1
Accounts Receivable, Net
1
1
1
Inventories
3
4
4
Total Current Liabilities
15
15
18
Payables & Accruals
8
8
10
ST Debt
7
7
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-32.85%
Free Cash Flow
- -
- -
-18.48%
Net Income, GAAP
- -
- -
-35.11%
Sales/Revenue/Turnover
- -
- -
127.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
1
1
1
1
3
2021
2
2
2
1
7
2022
2
2
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.03
-0.02
-0.04
- -
-0.29
2021
-0.02
-0.06
-0.01
- -
-0.19
2022
-0.03
-0.06
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Landec Corporation (LNDC)
Radient Technologies Inc. (RTI.V)
MedRx Co., Ltd (4586.T)
MPH Health Care AG (0W1Q.L)
Gage Growth Corp. (GAEGF)
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
Business
MPX International Corporation (MPXOF), founded in 2015 and headquartered in Toronto, Ontario, Canada, operates as a multinational diversified cannabis company focused on cultivating, manufacturing, extracting, and marketing cannabinoid-based products for medical and consumer markets across seven countries on five continents, including Canada, Switzerland, South Africa, Malta, Australia, Germany, and Thailand. The company offers a broad portfolio encompassing over 90 medical SKUs such as EU-GMP quality cannabis oils, derivatives, and tablets; more than 60 consumer and wellness SKUs including hemp prerolls, concentrates, extracts via supercritical CO2 and ethanol processes, distillates, nano-emulsions, and custom formulations utilizing nine cannabinoids; and branded products under HOLYWEED, beleaf, SALSUS, MPX labs, Canveda, SPARTAN WELLNESS, HIGH12, STRAIN REE, PENNIES, Kingsway, DAIZE, and alice, complemented by retail operations, e-commerce, and distribution channels targeting regulated medical and adult-use segments. Operations feature vertically integrated facilities from highly automated indoor grows to multi-hectare outdoor farms, GMP-compliant production sites, Swiss extraction labs, and retail outlets emphasizing education and premium experiences. Following its 2020 spin-off from iAnthus Capital Holdings via a $1.6 billion merger that segregated non-U.S. assets, MPX International completed the 2019 acquisition of a GMP-ready pharmaceutical facility in Malta from Alphafarma in partnership with Bortex for local manufacturing support and EU medical cannabis production, alongside the acquisition of HolyWeed as a Swiss premium organic cannabis entity, positioning it for expanded global distribution and innovation in cannabinoid therapeutics.